Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 4/20 | 0.47 |
| ▸ | GABRD | O14764 | 4/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.47 |
| ▸ | GABRE | P78334 | 4/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153353 | 0.85 | PTGS1 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL28204616 | 0.85 | GABRP (0.36) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2925692 | 0.84 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20594388 | 0.82 | KDM4E (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL5136122 | 0.82 | KAT8 (0.49) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL3297206 | 0.82 | GABRP (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31494238 | 0.81 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL2921220 | 0.81 | GABRP (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7538102 | 0.81 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL6859142 | 0.80 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248481-B | EZH2 covalent irreversible inhibitor, preparation method and application thereof | 中山大学 | 2023-03-24 | — | — | CN | disclosed |
| CN-113248481-A | EZH2 covalent irreversible inhibitor, preparation method and application thereof | 中山大学 | 2021-08-13 | — | — | CN | disclosed |
| US-8987461-B2 | Histone demethylase inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140194469-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-07-10 | — | — | US | disclosed |
| US-4493843-A | Indole and indoline carboxylic acid compounds and method of use | MAY & BAKER LIMITED (GB) | 1985-01-15 | — | — | US | disclosed |
| EP-0042298-B1 | INDOLE AND INDOLINE DERIVATIVES | MAY & BAKER LIMITED (GB) | 1984-09-12 | — | — | EP | disclosed |
| EP-0042298-A1 | Indole and indoline derivatives | MAY & BAKER LIMITED (GB) | 1981-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194469-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM5A, KDM1A | GABRP 2184/4885GABRD 2312/4885GABRA1 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.